Roberto Luzzati
Overview
Explore the profile of Roberto Luzzati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
2119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simonetti O, Armocida E, Rossi B, Samassa F, Gobbo Y, Luzzati R, et al.
Pathog Glob Health
. 2025 Feb;
119(1-2):22-28.
PMID: 39894965
In 1819, a puzzling outbreak of infectious blindness afflicted nearly all crew members and African slaves aboard the French vessel Le Rôdeur during the transatlantic slave trade. This paper investigates...
2.
Geremia N, Giovagnorio F, Colpani A, De Vito A, Botan A, Stroffolini G, et al.
Pharmaceuticals (Basel)
. 2025 Jan;
17(12.
PMID: 39770514
: Biofilm-associated infections frequently span multiple body sites and represent a significant clinical challenge, often requiring a multidisciplinary approach involving surgery and antimicrobial therapy. These infections are commonly healthcare-associated and...
3.
Benvenuto N, Di Bella S, Principe L, Luppino D, Conti J, Costantino V, et al.
Antibiotics (Basel)
. 2025 Jan;
13(12.
PMID: 39766588
: The early identification of infection-causing microorganisms through multiplex PCR panels enables prompt and targeted antibiotic therapy. This study aimed to assess the performance of the BioFire Joint Infection Panel...
4.
Geremia N, Di Bella S, Lovecchio A, Angelini J, DAvolio A, Luzzati R, et al.
Expert Rev Anti Infect Ther
. 2025 Jan;
:1-16.
PMID: 39746901
Introduction: Infectious disease treatments are transitioning from a one-size-fits-all approach to a more tailored approach. The increasing adoption of therapeutic drug monitoring (TDM) of antimicrobials is a clear example of...
5.
Di Bella S, Babich S, Luzzati R, Cavasio R, Massa B, Braccialarghe N, et al.
Infez Med
. 2024 Dec;
32(4):421-433.
PMID: 39660152
Crimean-Congo haemorrhagic fever (CCHF) is an emerging severe tick-borne illness. The expanding habitat of ticks, coupled with migratory birds harbouring CCHF-infected ticks, contributes to an increasing number of potential hosts....
6.
Geremia N, Sanson G, Principe L, Antonello R, Zerbato V, Luzzati R, et al.
Anaerobe
. 2024 Aug;
90:102901.
PMID: 39214165
Clostridium perfingens bloodstream infections (BSIs) can be associated with high mortality rates. We performed a subanalysis of all C. perfringens BSIs enrolled during a multicentric retrospective observational study (ITANAEROBY). Data...
7.
Zerbato V, Pol R, Sanson G, Suru D, Pin E, Tabolli V, et al.
Antibiotics (Basel)
. 2024 Jul;
13(7).
PMID: 39061283
Enterococci commonly cause nosocomial bloodstream infections (BSIs), and the global incidence of vancomycin-resistant enterococci (VRE) BSIs is rising. This study aimed to assess the risk factors for enterococcal BSIs and...
8.
Botan A, Campisciano G, Zerbato V, Di Bella S, Simonetti O, Busetti M, et al.
Diagnostics (Basel)
. 2024 Jul;
14(13).
PMID: 39001210
Effective treatment of infectious diseases requires prompt and accurate bacterial identification and tailored antimicrobial treatments. Traditional culture methods are considered the gold standard, but their effectiveness diminishes for fastidious and...
9.
Costantino V, Principe L, Mehat J, Busetti M, Piccirilli A, Perilli M, et al.
Antibiotics (Basel)
. 2024 Jun;
13(6).
PMID: 38927192
Infections caused by KPC-producing continue to pose a significant clinical challenge due to their emerging resistance to new antimicrobials. We investigated the association between two drugs whose roles have been...
10.
Tumbarello M, Raffaelli F, Giannella M, De Pascale G, Cascio A, De Rosa F, et al.
Open Forum Infect Dis
. 2024 Jun;
11(6):ofae273.
PMID: 38854388
Background: Meropenem-vaborbactam is a recent and promising option for the treatment of KPC-producing (KPC-Kp) infections, including those resistant to ceftazidime-avibactam. Methods: We conducted a retrospective analysis of observational data from...